Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
---|---|---|---|---|---|
Income Statement | |||||
Total Revenue | 28.94M | 4.80M | 0.00 | 0.00 | 0.00 |
Gross Profit | 19.68M | 1.11M | 0.00 | 0.00 | 0.00 |
EBITDA | 3.92M | -57.09M | -28.50M | -24.07M | -27.59M |
Net Income | -9.22M | -60.61M | -24.95M | -27.05M | -30.02M |
Balance Sheet | |||||
Total Assets | 38.91M | 63.92M | 76.38M | 81.39M | 47.29M |
Cash, Cash Equivalents and Short-Term Investments | 19.56M | 42.99M | 51.08M | 57.13M | 22.59M |
Total Debt | 15.04M | 11.59M | 12.32M | 4.65M | 7.68M |
Total Liabilities | 25.45M | 50.70M | 25.54M | 13.30M | 25.26M |
Stockholders Equity | 13.46M | 13.22M | 50.84M | 68.09M | 22.03M |
Cash Flow | |||||
Free Cash Flow | -43.93M | -22.91M | -26.56M | -23.67M | -23.21M |
Operating Cash Flow | -43.87M | -22.61M | -26.24M | -23.57M | -23.21M |
Investing Cash Flow | 29.37M | 1.44M | 4.01M | -38.22M | 16.67M |
Financing Cash Flow | 20.66M | 15.06M | 20.44M | 57.75M | 17.87M |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
---|---|---|---|---|---|---|---|
45 Neutral | $16.00M | ― | -46.42% | ― | 1.23% | 77.75% | |
45 Neutral | $20.36M | -19.77 | ― | ― | -100.00% | 98.69% | |
44 Neutral | $24.35M | -0.11 | ― | ― | ― | 60.64% | |
44 Neutral | $24.96M | -0.44 | ― | ― | ― | 32.57% | |
38 Underperform | $19.56M | -0.23 | ― | ― | ― | 18.73% | |
33 Underperform | $13.66M | -1.11 | ― | ― | ― | 47.86% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
On August 14, 2025, BioLineRx Ltd. announced its financial results for the second quarter of 2025, highlighting a strong cash position with a runway extended into the first half of 2027. The company is actively evaluating opportunities to expand its pipeline in oncology and rare diseases, with ongoing discussions with potential partners. Clinical trials, including the CheMo4METPANC Phase 2b trial for metastatic pancreatic cancer and studies on sickle cell disease, are progressing. Financially, the company reported $0.3 million in revenues for the quarter, primarily from royalties, and a net loss of $3.9 million. The company has significantly reduced its expenses following a transaction with Ayrmid in late 2024.
On June 29, 2025, BioLineRx Ltd. held its Annual General Meeting of Shareholders, where several key proposals were approved. These included the re-election of Dr. BJ Bormann and Dr. Raphael Hofstein as Class II directors, an increase in the company’s authorized share capital, the adoption of a renewed compensation policy for executives and directors, and the reappointment of Kesselman & Kesselman as the independent registered public accounting firm. These decisions are expected to strengthen the company’s governance and financial structure, potentially enhancing its market position and operational capabilities.